Act now to reduce cardiovascular (CV) risk in patients with elevated Lp(a), and don’t delay until results of Lp(a) lowering outcome trials are available. This was the key message from Professor Florian Kronenberg, from the Medical University of Innsbruck, Austria, in his wide-ranging review of ongoing Lp(a) outcomes trials and the importance of addressing traditional CV risk factors, including in primary prevention populations.1
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
